Search research articles
Contact Us
Filters
Showing results (11-20 of 107) with videos related to
Page
of 11
Sort By:
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
April 18, 2018
[Elimination of hepatitis C is possible]
Håvard Midgard, Knut Boe Kielland, Olav Dalgard
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
November 15, 2024
Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination
Robert Whittaker, Håvard Midgard, Olav Dalgard, et al.
Scandinavian Journal of Gastroenterology
|
October 14, 2014
HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984
Knut Boe Kielland, Ellen J Amundsen, Olav Dalgard
Scandinavian Journal of Gastroenterology
|
August 12, 2010
Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
Håvard Midgard, Christina Bang, Nils Raknerud, et al.
Journal of Hepatology
|
August 13, 2015
Debilitating fatigue as a treatment indication in chronic hepatitis C
Simon Hjerrild, Olav Dalgard, Peer Brehm Christensen, et al.
Journal of Viral Hepatitis
|
September 22, 2025
Linkage to Care, Retention in Care and Treatment Uptake Among Patients Diagnosed With Chronic Hepatitis B in Norway, 2008-2022
Beatriz Valcarcel Salamanca, Asgeir Johannessen, Olav Dalgard, et al.
European Journal of Gastroenterology & Hepatology
|
February 16, 2010
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials
Olav Dalgard, Kristian Bjoro, Helmer Ring-Larsen, et al.
Journal of Hepatology
|
September 11, 2012
All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study
Knut Boe Kielland, Kjell Skaug, Ellen J Amundsen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 26, 2013
Hepatitis C virus reinfection following treatment among people who use drugs
Bart P Grady, Janke Schinkel, Xiomara V Thomas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 2, 2024
Treatment Completion and Sustained Virologic Response in the Context of Hepatitis C Virus Elimination: Time to Let Go of the Reins?
Håvard Midgard, Kristian B Malme, Ane-Kristine Finbråten, et al.
Page
of 11
Search research articles
Search
Showing results (11-20 of 107) with videos related to
Sort By:
Page
of 11
Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|
April 18, 2018
[Elimination of hepatitis C is possible]
Håvard Midgard, Knut Boe Kielland, Olav Dalgard
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin
|
November 15, 2024
Treatment uptake among notified cases of hepatitis C virus infection in Norway, 1990 to 2022: a registry-based study to monitor progress towards elimination
Robert Whittaker, Håvard Midgard, Olav Dalgard, et al.
Scandinavian Journal of Gastroenterology
|
October 14, 2014
HCV treatment uptake in people who have injected drugs - observations in a large cohort that received addiction treatment 1970-1984
Knut Boe Kielland, Ellen J Amundsen, Olav Dalgard
Scandinavian Journal of Gastroenterology
|
August 12, 2010
Liver fibrosis in hepatitis C patients of Pakistani versus Scandinavian origin
Håvard Midgard, Christina Bang, Nils Raknerud, et al.
Journal of Hepatology
|
August 13, 2015
Debilitating fatigue as a treatment indication in chronic hepatitis C
Simon Hjerrild, Olav Dalgard, Peer Brehm Christensen, et al.
Journal of Viral Hepatitis
|
September 22, 2025
Linkage to Care, Retention in Care and Treatment Uptake Among Patients Diagnosed With Chronic Hepatitis B in Norway, 2008-2022
Beatriz Valcarcel Salamanca, Asgeir Johannessen, Olav Dalgard, et al.
European Journal of Gastroenterology & Hepatology
|
February 16, 2010
In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials
Olav Dalgard, Kristian Bjoro, Helmer Ring-Larsen, et al.
Journal of Hepatology
|
September 11, 2012
All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: a controlled study
Knut Boe Kielland, Kjell Skaug, Ellen J Amundsen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
July 26, 2013
Hepatitis C virus reinfection following treatment among people who use drugs
Bart P Grady, Janke Schinkel, Xiomara V Thomas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
June 2, 2024
Treatment Completion and Sustained Virologic Response in the Context of Hepatitis C Virus Elimination: Time to Let Go of the Reins?
Håvard Midgard, Kristian B Malme, Ane-Kristine Finbråten, et al.
Page
of 11